Want to see NKTX full AI Analyst Report?
Top Page
Nkarta
(NASDAQ:NKTX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$2.50
▲(10.13% Upside)
Action:Reiterated
Date:08/11/26
The score is primarily held down by weak financial performance (pre-revenue status, sizable ongoing losses, and continued cash burn with declining equity). Technical signals are mixed but lean bearish due to a negative MACD and price below key mid-term moving averages, while valuation provides limited support given a negative P/E and no dividend. Governance-related corporate events are a modest positive but not enough to offset the fundamentals.
Positive Factors
FDA agreement enabling outpatient dosing
The FDA agreement to allow outpatient dosing and Nkarta’s start of community-based site dosing materially improves delivery scalability and patient access. Over 2-6 months this reduces reliance on inpatient infrastructure, lowers per-treatment logistics and cost, and can speed enrollment and commercial rollout pathways.
Negative Factors
Pre-revenue with persistent operating losses
Nkarta has no product revenue and substantial recurring operating losses, meaning it lacks internal commercial cash generation. Over the next several months this keeps the company dependent on external funding and prolongs the timeline to positive margin sustainability and self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA agreement enabling outpatient dosing
The FDA agreement to allow outpatient dosing and Nkarta’s start of community-based site dosing materially improves delivery scalability and patient access. Over 2-6 months this reduces reliance on inpatient infrastructure, lowers per-treatment logistics and cost, and can speed enrollment and commercial rollout pathways.
Read all positive factors
Nkarta (NKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$172.62M
Dividend YieldN/A
Average Volume (3M)730.63K
Price to Earnings (P/E)―
Beta (1Y)1.85
Revenue GrowthN/A
EPS Growth-6.70%
CountryUS
Employees108
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.57
Shares Outstanding71,624,794
10 Day Avg. Volume633,109
30 Day Avg. Volume730,626
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.75Price Target Upside417.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.59
Revenue Forecast (FY)N/A
Nkarta Business Overview & Revenue Model
Company Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR ...
How the Company Makes Money
Nkarta does not sell approved products and, as a clinical-stage biotechnology company, has historically generated little to no recurring commercial revenue. The company’s funding has primarily come from external financing (e.g., equity offerings a...
Nkarta Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.34M | -9.19M | 0.00 | -5.87M | 0.00 | 0.00 |
| EBITDA | -107.69M | -94.89M | -99.64M | -120.48M | -105.61M | -84.32M |
| Net Income | -117.32M | -104.08M | -108.79M | -117.50M | -113.84M | -86.08M |
Balance Sheet | ||||||
| Total Assets | 337.64M | 404.21M | 501.20M | 378.88M | 472.94M | 273.90M |
| Cash, Cash Equivalents and Short-Term Investments | 182.76M | 276.28M | 267.35M | 248.19M | 352.14M | 238.09M |
| Total Debt | 73.54M | 76.42M | 80.27M | 88.34M | 82.93M | 12.46M |
| Total Liabilities | 89.91M | 91.88M | 93.23M | 105.60M | 100.73M | 22.94M |
| Stockholders Equity | 247.74M | 312.32M | 407.98M | 273.29M | 372.21M | 250.97M |
Cash Flow | ||||||
| Free Cash Flow | -93.90M | -89.91M | -104.11M | -114.31M | -104.11M | -72.95M |
| Operating Cash Flow | -92.76M | -88.70M | -99.70M | -86.16M | -57.00M | -67.93M |
| Investing Cash Flow | 63.55M | 100.32M | -129.56M | 79.02M | -184.69M | 32.53M |
| Financing Cash Flow | 746.00K | 141.00K | 226.08M | 691.00K | 219.01M | 1.20M |
Nkarta Technical Analysis
Positive
2.27
Price Trends
2.62
Negative
2.70
Negative
2.39
Positive
Market Momentum
-0.05
Negative
54.52
Neutral
81.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NKTX, the sentiment is Positive. The current price of 2.27 is below the 20-day moving average (MA) of 2.30, below the 50-day MA of 2.62, and below the 200-day MA of 2.39, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 54.52 is Neutral, neither overbought nor oversold. The STOCH value of 81.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NKTX.
Nkarta Risk Analysis
Nkarta disclosed 80 risk factors in its most recent earnings report. Nkarta reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nkarta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $225.04M | 6.50 | 42.57% | ― | 234.18% | ― | |
56 Neutral | $747.71M | -15.02 | -43.57% | ― | -66.63% | 57.89% | |
52 Neutral | $681.28M | -17.81 | -147.78% | ― | ― | -13.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $514.25M | -4.21 | -45.45% | ― | 2.33% | 36.86% | |
46 Neutral | $41.09M | -1.10 | 241.39% | ― | ― | 36.06% | |
44 Neutral | $172.62M | -1.62 | -39.64% | ― | ― | -6.70% |
* Healthcare Sector Average
NKTX
Nkarta
2.54
0.28
12.39%
CGEN
Compugen
2.44
1.00
69.44%
CCCC
C4 Therapeutics
4.21
1.61
61.92%
STTK
Shattuck Labs
7.66
6.65
658.42%
TVGN
Tevogen Bio Holdings
6.42
-39.53
-86.03%
NVCT
Nuvectis Pharma
23.33
16.79
256.73%
Nkarta Corporate Events
Executive/Board ChangesShareholder Meetings
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
Positive
Jun 11, 2026
At its 2026 annual meeting of stockholders held on June 10, 2026, Nkarta, Inc. shareholders elected Ali Behbahani and Zachary Scheiner as Class III directors to serve until the 2029 annual meeting, and ratified Ernst Young LLP as the company̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.